You are standing in a pharmacy at nine in the evening. On one shelf is a packet of antihistamine sleeping tablets — diphenhydramine or doxylamine, sold under names like Nytol, ZzzQuil and Unisom. On another is a bottle of Sleep Formula. You want to know which one works.
The honest answer is not the one we would prefer to give. For a single bad night, the antihistamine has better evidence for sedation than our product does. What it also has is tolerance that arrives within days, a documented next-morning hangover, and an anticholinergic profile geriatric guidelines tell prescribers to avoid in older patients. Sleep Formula has none of those problems and a thinner efficacy file. Neither is the right answer to insomnia that has lasted weeks.
What the antihistamines are, and what they do
The US over-the-counter monograph for nighttime sleep aids (21 CFR Part 338) names two permitted actives: diphenhydramine hydrochloride at 50mg at bedtime, and diphenhydramine citrate at 76mg. Doxylamine succinate is also widely sold for sleep. Both are first-generation H1 antihistamines that cross the blood–brain barrier freely, which is why they make you drowsy: the sedation is an off-target effect of an allergy drug, repurposed.
One point worth carrying into the aisle: the same brand name can cover different actives in different products and countries. Read the ingredient, not the front of the box.
They do work, modestly, for a short while. The best-designed trial to test this was a nine-centre US study of 184 adults with mild insomnia, published in Sleep in 2005. Diphenhydramine 50mg nightly produced significantly greater increases in sleep efficiency than placebo over the first 14 days, and a non-significant trend toward longer total sleep time. Anyone telling you these drugs are placebo is overstating the case.
But read the rest of that trial. There was no significant group difference on any sleep-continuity variable measured by polysomnography — the objective recording did not confirm what the diaries reported.
Tolerance: three days
This is the most useful number in the comparison. Fifteen healthy men took diphenhydramine 50mg or placebo twice daily for four days in a randomised double-blind crossover. On day 1, both objective and subjective sleepiness were significantly higher on the drug. By day 4, sleepiness on diphenhydramine was indistinguishable from placebo, and the performance impairment it had caused was completely reversed. The authors concluded tolerance was complete by the end of three days.
You do not have to take our word for it. The UK Summary of Product Characteristics for diphenhydramine 50mg tablets says plainly: "Tolerance may develop with continuous use", and "This medicinal product should not be used continuously for longer than 2 weeks without consulting a doctor." The US label carries the same two-week boundary, with the reason attached: "Insomnia may be a symptom of serious underlying medical illness."
The next morning
A randomised, double-blind, placebo-controlled crossover study in 22 healthy men gave diphenhydramine 50mg, zolpidem 10mg or placebo before sleep, then tested them the next morning and afternoon. Diphenhydramine was significantly associated with next-day sleepiness and reduced psychomotor performance; zolpidem showed no carryover against placebo.
The pharmacokinetics explain it. The UK SPC gives diphenhydramine an elimination half-life of 2.4–9.3 hours in healthy adults; a 1990 study measured 9.2 ± 2.5 hours in young adults and 13.5 ± 4.2 hours in older adults. Doxylamine is slower still — in a head-to-head study, its elimination half-life averaged 10.1 hours against diphenhydramine's 6.0. Take either at 11pm and a meaningful fraction is still circulating at breakfast.
The finding that should worry anyone who drives: in the Iowa Driving Simulator, 40 licensed drivers performed worse after diphenhydramine 50mg than after alcohol at roughly 0.1% blood alcohol. That was a single daytime dose before an hour of driving, not a next-morning test, so it does not transfer directly to bedtime use. What does transfer is the study's other conclusion: self-reported drowsiness did not predict impairment.
In fairness, the 2005 insomnia trial reported no significant residual effects and no rebound insomnia on its own measures. The morning-after evidence is strong but not unanimous.
The anticholinergic question, reported straight
First-generation antihistamines are strongly anticholinergic, and there is a large observational literature linking cumulative anticholinergic exposure to later dementia. It deserves neither dismissal nor a scare, so here is what it says.
The Adult Changes in Thought cohort followed 3,434 people aged 65 and over; 797 developed dementia over a mean 7.3 years. The highest cumulative exposure band carried an adjusted hazard ratio of 1.54 (95% CI 1.21–1.96) against no use, with a significant dose-response trend — but the three lower bands all had confidence intervals crossing 1.00. First-generation antihistamines were among the three most-used classes in that cohort.
The larger UK study complicates things. Across 58,769 dementia cases and 225,574 matched controls, total anticholinergic exposure above 1,095 standardised daily doses gave an odds ratio of 1.49 (1.44–1.54). Broken down by class, the significant signals were antidepressants, antiparkinson drugs, antipsychotics, bladder antimuscarinics and antiepileptics. Antihistamines were not among them: the fully adjusted odds ratio at the highest exposure was 1.14 (0.98–1.34), crossing 1.00. The authors flagged their own caveat — exposure misclassification "might explain the lack of association for antihistamines", and in the UK these drugs are mostly bought over the counter, so prescription records miss most of the real exposure.
None of this establishes causation, and a 2019 commentary in the Journal of Clinical Psychiatry argued the case for causality is weak: only three of eleven drug categories were consistently associated, confounding by indication is plausible for several, and the associations were stronger for vascular dementia than Alzheimer's. We set out the whole literature, including where it contradicts itself, in anticholinergic burden and brain fog, and dementia risk factors generally in our guide to the fourteen modifiable dementia risk factors.
What is not in dispute is the guidance built on the short-term effects. The 2023 American Geriatrics Society Beers Criteria list first-generation antihistamines — diphenhydramine and doxylamine both named — as medications to avoid in adults 65 and over: a strong recommendation on moderate-quality evidence, with a rationale that includes falling clearance with age and that "tolerance develops when used as hypnotic".
Where our own evidence is thinner
Now the part that costs us the sale. The 2017 American Academy of Sleep Medicine guideline on pharmacologic treatment of chronic insomnia reviewed individual agents and issued recommendations against diphenhydramine — and also against melatonin, tryptophan and valerian. All four are weak recommendations on low-quality evidence. Three of those four ingredients are in Sleep Formula. One panel looked at the OTC drug and at most of our botanicals and endorsed none of them.
A 2024 umbrella review in European Neuropsychopharmacology synthesised eight systematic reviews of valerian and found a good safety profile but no evidence of efficacy for insomnia; subjective sleep-quality improvement appeared, but effectiveness "has not been demonstrated with quantitative or objective measurements". We cover that literature in full in valerian root for sleep. In the 2005 head-to-head trial, the valerian-hops arm's reduction in sleep latency against placebo was explicitly non-significant, while diphenhydramine's sleep-efficiency gain was significant — and that arm used roughly 374mg of valerian native extract plus hops, more valerian than Sleep Formula's 150mg and a different preparation.
Several other ingredients sit below their studied doses. The chamomile insomnia trial used 270mg twice daily — 540mg a day — and found no significant difference from placebo on any sleep-diary measure; Sleep Formula has 100mg. A tryptophan meta-analysis found the benefit on wake-after-sleep-onset concentrated at 1g or more; Sleep Formula has 100mg. We go through all seven ingredients in inside Sleep Formula, and separately on L-tryptophan, chamomile, whether oral GABA reaches the brain at all, and the real melatonin dose-response evidence.
So the comparison is not "ours works, theirs doesn't." For acute sedation on one night, diphenhydramine has the stronger file.
What Sleep Formula actually offers instead
Three things, none of which is better sedation.
- Nothing to develop tolerance to on a three-day timescale. There is no published equivalent of the diphenhydramine tolerance finding for these botanicals — partly because the effect being tolerated is smaller.
- No anticholinergic load. Valerian, chamomile, lemon balm, passion flower, GABA, tryptophan and melatonin are not muscarinic antagonists. Whatever the dementia literature eventually settles on, this product is not part of that question.
- Every milligram on the label. All seven ingredients are disclosed individually — which is what let us write the paragraph above. Sleep Formula is the one product in our range that is fully disclosed; the others are not, and we do not claim otherwise.
Against our other night-time product, we compare the two in Sleep Formula vs Sleep Support.
The answer that is neither product
If sleeplessness has gone on for more than a couple of weeks, the question is not which box to buy. The American College of Physicians recommends that all adult patients receive cognitive behavioural therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder — a strong recommendation on moderate-quality evidence, the highest grade anything in this article carries. Medication, where it is added at all, is a shared decision afterwards. We have written that up in full in CBT-I: the sleep treatment with better evidence than any supplement.
Two things are worth ruling out before either shelf. Some people sleeping badly are not short of sedation but short of airway — our STOP-BANG explainer takes two minutes. Others are sleeping normally and expecting the wrong number, which how much sleep adults actually need covers.
For whether an antihistamine sleep aid is a sensible idea for you specifically — with your age, your other medicines and your history in front of them — ask a pharmacist. They are standing in the same shop, they can check interactions against everything else you take, and the conversation is free.
This article is for information only and is not medical advice. Proco supplements are food supplements, not medicines, and are not intended to diagnose, treat, cure or prevent any disease. Do not start, stop or change any medicine on the basis of this article. Speak to your doctor or pharmacist about medicines, and if poor sleep persists, see your GP.
Sources: Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. "Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial." Sleep 2005;28(11):1465–1471. DOI: 10.1093/sleep/28.11.1465. — Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. "Tolerance to daytime sedative effects of H1 antihistamines." Journal of Clinical Psychopharmacology 2002;22(5):511–515. DOI: 10.1097/00004714-200210000-00012. — Katayose Y, Aritake S, Kitamura S, Enomoto M, Hida A, Takahashi K, Mishima K. "Carryover effect on next-day sleepiness and psychomotor performance of nighttime administered antihistaminic drugs: a randomized controlled trial." Human Psychopharmacology 2012;27(5):428–436. DOI: 10.1002/hup.2244. — Weiler JM, Bloomfield JR, Woodworth GG, et al. "Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator." Annals of Internal Medicine 2000;132(5):354–363. DOI: 10.7326/0003-4819-132-5-200003070-00004. — Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE. "Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children." Journal of Clinical Pharmacology 1990;30(7):665–671. DOI: 10.1002/j.1552-4604.1990.tb01871.x. — Luna BG, Scavone JM, Greenblatt DJ. "Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives." Journal of Clinical Pharmacology 1989;29(3):257–260. DOI: 10.1002/j.1552-4604.1989.tb03323.x. — Gray SL, Anderson ML, Dublin S, et al. "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study." JAMA Internal Medicine 2015;175(3):401–407. DOI: 10.1001/jamainternmed.2014.7663. — Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. "Anticholinergic drug exposure and the risk of dementia: a nested case-control study." JAMA Internal Medicine 2019;179(8):1084–1093. DOI: 10.1001/jamainternmed.2019.0677. — Andrade C. "Anticholinergic drug exposure and the risk of dementia: there is modest evidence for an association but not for causality." Journal of Clinical Psychiatry 2019;80(4):19f13000. DOI: 10.4088/jcp.19f13000. — 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society 2023;71(7):2052–2081. DOI: 10.1111/jgs.18372. — Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline." Journal of Clinical Sleep Medicine 2017;13(2):307–349. DOI: 10.5664/jcsm.6470. — Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. "Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians." Annals of Internal Medicine 2016;165(2):125–133. DOI: 10.7326/M15-2175. — Valente V, Machado D, Jorge S, Drake CL, Marques DR. "Does valerian work for insomnia? An umbrella review of the evidence." European Neuropsychopharmacology 2024;82:6–28. DOI: 10.1016/j.euroneuro.2024.01.008. — Zick SM, Wright BD, Sen A, Arnedt JT. "Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study." BMC Complementary and Alternative Medicine 2011;11:78. DOI: 10.1186/1472-6882-11-78. — Sutanto CN, Loh WW, Kim JE. "The impact of tryptophan supplementation on sleep quality: a systematic review, meta-analysis, and meta-regression." Nutrition Reviews 2022;80(2):306–316. DOI: 10.1093/nutrit/nuab027. — US Code of Federal Regulations, Title 21 Part 338, "Nighttime sleep-aid drug products for over-the-counter human use" (eCFR). — Summary of Product Characteristics, Diphenhydramine Hydrochloride 50 mg Tablets, electronic medicines compendium (emc).